Search

Displaying results 4151 - 4160 of 4233 in total
  1. Drug

    ZYCOV-D

    go.drugbank.com/drugs/DB15892
    Experimental

    As of August, 2020 the candidate is in Phase II clinical trials[A219758].

  2. Drug

    PR-104

    go.drugbank.com/drugs/DB05968
    Investigational

  3. Drug

    PRX-07034

    go.drugbank.com/drugs/DB05993
    Experimental

  4. Drug

    SPC2968

    go.drugbank.com/drugs/DB06351
    Investigational

    SPC2968 is a synthetic antisense oligodeoxynucleotide targeting hypoxia-inducible factor-1alpha (HIF-1alpha). It was under investigation in clinical trial NCT02564614 (A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic ...

  5. Drug

    VPM1002

    go.drugbank.com/drugs/DB15801
    Investigational

    As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials. … VPM1002 is a recombinant BCG vaccine candidate expressing listeriolysin and deficient in urease that is generated in the genetic background of BCG Prague as it has a better safety profile than some other

  6. Drug

    Darapladib

    go.drugbank.com/drugs/DB06311
    Investigational

  7. Drug

    Amniotic Epithelial Cells

    go.drugbank.com/drugs/DB15868
    Investigational

    Amniotic epithelial cells (AEC) are multipotent stem-like cells derived from the basement collagenous membrane of the human amnion, the layer of the placenta closest to the fetus. These cells are potential candidates for allogeneic cell ...

  8. Drug

    GC-373

    go.drugbank.com/drugs/DB15797
    Experimental

    It is an inhibitor of M<sup>pro</sup> (otherwise known as 3CL<sup>pro</sup>), a viral encoded protease that cleaves and activates functional proteins involved in viral replication and transcription[A219036

  9. Drug

    Hydroxyurea

    go.drugbank.com/drugs/DB01005
    ApprovedInvestigational

    Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Althou...

  10. Drug

    IL-2 pDNA

    go.drugbank.com/drugs/DB05935
    Experimental

    Vical incorporated has initiated a human Phase 1 study of an investigational method of delivering interleukin-2 (IL-2), a potent immune system stimulant, for patients with recurrent metastatic melanoma.